Does the media refer more to NKTX or ESPR?

In the previous week, Nkarta and Nkarta both had 4 articles in the media. Esperion Therapeutics' average media sentiment score of 1.42 beat Nkarta's score of 0.47 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Esperion Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ANRO or NKTX?

Alto Neuroscience is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is ANRO or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Nkarta N/A -30.90% -24.20%

Which has higher earnings and valuation, ANNX or NKTX?

Annexon is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is ANNX or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Nkarta N/A -30.90% -24.20%

Which has better valuation and earnings, VOR or NKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is VOR or NKTX more profitable?

Vor Biopharma's return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Nkarta N/A -30.90% -24.20%

Does the media favor VOR or NKTX?

In the previous week, Nkarta had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.94 beat Nkarta's score of 0.47 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, DSGN or NKTX?

Design Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is DSGN or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Nkarta N/A -30.90% -24.20%

Does the media favor DSGN or NKTX?

In the previous week, Nkarta had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Nkarta and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.04 beat Nkarta's score of 0.47 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nkarta (NKTX) Competitors

$2.83 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$2.80 -0.04 (-1.24%)

As of 04:01 AM Eastern

Compare

NKTX vs. ESPR, ANRO, ANNX, VOR, and DSGN

Should you buy Nkarta stock or one of its competitors? MarketBeat compares Nkarta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nkarta include Esperion Therapeutics (ESPR), Alto Neuroscience (ANRO), Annexon (ANNX), Vor Biopharma (VOR), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry.

How does Nkarta compare to Esperion Therapeutics?

Nkarta (NASDAQ:NKTX) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Esperion Therapeutics has higher revenue and earnings than Nkarta. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Nkarta currently has a consensus target price of $10.75, suggesting a potential upside of 279.86%. Esperion Therapeutics has a consensus target price of $5.54, suggesting a potential upside of 74.76%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Nkarta and Nkarta both had 4 articles in the media. Esperion Therapeutics' average media sentiment score of 1.42 beat Nkarta's score of 0.47 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Esperion Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has a net margin of 0.12% compared to Nkarta's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Esperion Therapeutics	0.12%	-0.14%	0.12%

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 9.8% of Nkarta shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Nkarta has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Summary

Esperion Therapeutics beats Nkarta on 8 of the 15 factors compared between the two stocks.

How does Nkarta compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

80.5% of Nkarta shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Nkarta had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Nkarta and 0 mentions for Alto Neuroscience. Nkarta's average media sentiment score of 0.47 beat Alto Neuroscience's score of 0.00 indicating that Nkarta is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Nkarta	Neutral

Alto Neuroscience currently has a consensus target price of $35.25, suggesting a potential upside of 31.36%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 279.86%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Nkarta's return on equity of -30.90% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Nkarta	N/A	-30.90%	-24.20%

Alto Neuroscience has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Alto Neuroscience is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Summary

Nkarta beats Alto Neuroscience on 10 of the 14 factors compared between the two stocks.

How does Nkarta compare to Annexon?

Annexon (NASDAQ:ANNX) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Annexon presently has a consensus price target of $16.00, suggesting a potential upside of 191.28%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 279.86%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Nkarta had 3 more articles in the media than Annexon. MarketBeat recorded 4 mentions for Nkarta and 1 mentions for Annexon. Annexon's average media sentiment score of 1.87 beat Nkarta's score of 0.47 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Very Positive
Nkarta	Neutral

Nkarta's return on equity of -30.90% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Nkarta	N/A	-30.90%	-24.20%

Annexon is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

80.5% of Nkarta shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Nkarta beats Annexon on 9 of the 13 factors compared between the two stocks.

How does Nkarta compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Nkarta (NASDAQ:NKTX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Vor Biopharma's return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Nkarta	N/A	-30.90%	-24.20%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Vor Biopharma currently has a consensus target price of $42.25, suggesting a potential upside of 162.42%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 279.86%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Nkarta had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.94 beat Nkarta's score of 0.47 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Vor Biopharma beats Nkarta on 7 of the 11 factors compared between the two stocks.

How does Nkarta compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Nkarta had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Nkarta and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.04 beat Nkarta's score of 0.47 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Design Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 23.60%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 279.86%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Nkarta's return on equity of -30.90% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Nkarta	N/A	-30.90%	-24.20%

Design Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Design Therapeutics beats Nkarta on 7 of the 13 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$202.46M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-2.11	21.75	25.89	24.17
Price / Sales	N/A	334.18	546.41	101.77
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.64	8.31	10.79	6.38
Net Income	-$104.08M	$23.92M	$3.58B	$337.00M
7 Day Performance	1.43%	1.93%	1.97%	-0.20%
1 Month Performance	-12.92%	-0.41%	-0.24%	-1.40%
1 Year Performance	70.48%	65.22%	34.40%	27.76%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	4.2407 of 5 stars	$2.83 flat	$10.75 +279.9%	+70.5%	$202.46M	N/A	N/A	140	Gap Down High Trading Volume
ESPR Esperion Therapeutics	2.4299 of 5 stars	$3.16 +0.3%	$5.54 +75.3%	+219.0%	$811.73M	$403.14M	N/A	200
ANRO Alto Neuroscience	1.9454 of 5 stars	$22.93 +0.8%	$35.25 +53.7%	+1,044.3%	$804.71M	N/A	N/A	N/A	Gap Down
ANNX Annexon	3.6096 of 5 stars	$5.04 +2.9%	$16.00 +217.5%	+127.9%	$802.83M	N/A	N/A	60	Positive News Gap Down
VOR Vor Biopharma	2.3406 of 5 stars	$14.94 +3.1%	$42.25 +182.8%	-24.1%	$785.16M	N/A	N/A	140	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. ESPR, ANRO, ANNX, VOR, and DSGN

How does Nkarta compare to Esperion Therapeutics?

Summary

How does Nkarta compare to Alto Neuroscience?

Summary

How does Nkarta compare to Annexon?

Summary

How does Nkarta compare to Vor Biopharma?

Summary

How does Nkarta compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. ESPR, ANRO, ANNX, VOR, and DSGN

How does Nkarta compare to Esperion Therapeutics?

Which has better earnings and valuation, NKTX or ESPR?

Do analysts recommend NKTX or ESPR?

Does the media refer more to NKTX or ESPR?

Is NKTX or ESPR more profitable?

Do institutionals & insiders hold more shares of NKTX or ESPR?

Which has more risk and volatility, NKTX or ESPR?

Summary

How does Nkarta compare to Alto Neuroscience?

Do institutionals and insiders have more ownership in ANRO or NKTX?

Does the media favor ANRO or NKTX?

Do analysts recommend ANRO or NKTX?

Is ANRO or NKTX more profitable?

Which has more risk & volatility, ANRO or NKTX?

Which has stronger earnings and valuation, ANRO or NKTX?

Summary

How does Nkarta compare to Annexon?

Do analysts rate ANNX or NKTX?

Does the media refer more to ANNX or NKTX?

Is ANNX or NKTX more profitable?

Which has higher earnings and valuation, ANNX or NKTX?

Which has more volatility and risk, ANNX or NKTX?

Do insiders and institutionals have more ownership in ANNX or NKTX?

Summary

How does Nkarta compare to Vor Biopharma?

Is VOR or NKTX more profitable?

Which has better valuation and earnings, VOR or NKTX?

Do analysts rate VOR or NKTX?

Do institutionals & insiders hold more shares of VOR or NKTX?

Does the media favor VOR or NKTX?

Which has more risk & volatility, VOR or NKTX?

Summary

How does Nkarta compare to Design Therapeutics?

Does the media favor DSGN or NKTX?

Do institutionals and insiders hold more shares of DSGN or NKTX?

Do analysts rate DSGN or NKTX?

Is DSGN or NKTX more profitable?

Which has higher valuation & earnings, DSGN or NKTX?

Which has more volatility & risk, DSGN or NKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools